Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01804465 | Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2021 |
| clinicaltrials |
| NCT02981368 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer(OSPREY) | completed | Phase 2 / Phase 3 | 385 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 9, 2021 | clinicaltrials |
| NCT00214136 | Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes | completed | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02463799 | Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02867020 | Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | completed | Phase 2 | 128 | Latin American Cooperative Oncology GroupOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00667862 | Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01706458 | Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT01254513 | Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients(GERICO10) | completed | Phase 2 | 66 | UNICANCEROTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02229734 | Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2(FASTR-2) | completed | Phase 2 | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02559115 | 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT00087165 | GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02046837 | An Exercise Trial and Economic Analysis in Men With Prostate Cancer(ADT Ex RCT) | completed | Phase 2 | 59 | University Health Network, TorontoOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00350051 | ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | completed | Phase 2 | 53 | BayerINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00737893 | Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy(ERECT) | completed | Phase 2 | 56 | Johns Hopkins UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01317199 | Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT01615120 | Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer | completed | Phase 2 | 77 | GTxINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01748500 | Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 21 | University Health Network, TorontoOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT03179410 | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer(PICK-NEPC) | completed | Phase 2 | 15 | Andrew J. Armstrong, MDOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02860819 | Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer | completed | Phase 2 | 15 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03263780 | High Resolution PET-MRI Before Prostate Cancer HIFU | completed | Phase 2 | 21 | Timothy J. DaskivichOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02628041 | HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer(HDRvsLDR) | completed | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT01341652 | Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer | completed | Phase 2 | 99 | University of Wisconsin, MadisonOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03418324 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | completed | Phase 2 | 11 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT02611882 | Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients(PSMA PET) | completed | Phase 2 | 225 | Thomas HopeOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT03348527 | A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer | completed | Phase 2 | 61 | Lidds ABINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT02919111 | Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients(PSMA PreRP) | completed | Phase 2 / Phase 3 | 299 | University of California, San FranciscoOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01940276 | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | completed | Phase 2 | 100 | Duke UniversityOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01051570 | Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | completed | Phase 2 | 26 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT00428714 | Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy | completed | Phase 2 | 73 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02397408 | 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer | completed | Phase 2 | 18 | University of California, San FranciscoOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02036060 | Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.(ABIDO) | completed | Phase 2 | 119 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT00466440 | A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | completed | Phase 2 | 108 | Eli Lilly and CompanyINDUSTRY | 3 | Nov 6, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00970203 | Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | completed | Phase 2 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02199197 | Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | completed | Phase 2 | 49 | University of UtahOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00006365 | External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 138 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2021source: clinicaltrials